5% capsaicin topical liquid (CGS-200-5) / Aosaikang Pharma, Astellas - LARVOL DELTA

The Safety and Pharmacokinetics of ASKC200 in Osteoarthritic Knee Pain (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Jiangsu Aosaikang Pharmaceutical Co., Ltd.

New P1 trial • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

Propella Therapeutics Announces Licensing Agreement with Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm) for Development and Commercial Rights to CGS-200-5 in Greater China (GlobeNewswire) - "Propella Therapeutics, Inc...and Jiangsu Aosaikang Pharmaceutical Co. Ltd...today announced that the companies have entered into an exclusive licensing agreement for CGS-200-5, a clinical-stage topical treatment that is being developed for the treatment of pain in patients with moderate to severe osteoarthritis (OA) of the knee. Under the terms of the agreement, ASK Pharm will have exclusive rights to develop, manufacture and commercialize CGS-200-05 for the Greater China region. As part of the agreement, Propella will receive an upfront payment and is entitled to receive regulatory and sales milestones, as well as royalties on future product sales..."

Licensing / partnership • CNS Disorders • Osteoarthritis • Pain

New Osteoarthritis (OA) treatment guidelines issued…Expert Medical Organization conditionally recommends the use of topical Capsaicin for pain due to OA of the knee (Businesswire) - "Vizuri Health Sciences...reports that the American College of Rheumatology...has announced updated 2019 treatment guidelines for the management of OA of the hand, hip, and knee....Key revisions to the 2019 OA Treatment Guidelines highlighted by ACR include: A conditional recommendation for the use of topical capsaicin in patients with OA of the knee (the 2012 guideline contained a conditional recommendation against topical capsaicin)."

Clinical guideline

A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200-1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin) (ACR-ARHP 2019) - "CGS-200-5 was well-tolerated and efficacious following application to both knees for 60 minutes on 4 consecutive days. Due to the significant efficacy and good safety and tolerability observed in this study, further clinical development of CGS-200-5 is warranted."

Clinical • P2 data

Vizuri Health Sciences LLC to present CGS-200-5 knee pain results at the American College of Rheumatology Annual Meeting (Businesswire) - "Vizuri Health Sciences LLC...today announced that it has been selected to make an oral presentation of findings from a randomized, double blind Phase 2 osteoarthritis (OA) knee pain study (VZU00025, NCT03528369) at the American College of Rheumatology and the Association of Rheumatology Health Professionals’ 2019 Annual Meeting, which will take place from November 8-13 in Atlanta, Georgia."

P2 data